This protocol addresses adults with type 1 diabetes who also have obesity, defined as BMI ≥30.0 kg/m² (or ≥27.5 kg/m² in Asian American individuals). The presence of type 1 diabetes introduces specific safety considerations that make standard obesity treatment approaches insufficient without modification.
Obesity management strategies in this population include GLP-1 receptor agonist–based therapy — though the way this therapy is initiated and conducted differs importantly from general-population protocols. The full structured regimen specifies how these differences are addressed in practice.
DOI: 10.2337/dc26-S008
Apply obesity management strategies used in the general adult population, including GLP-1 RA–based therapy and metabolic surgery, to adults with type 1 diabetes who have obesity (BMI ≥30.0 kg/m², or ≥27.5 kg/m² in Asian American individuals).
For treatment of obesity in people with type 1 diabetes, initiation of GLP-1 RA or dual GIP and GLP-1 RA should follow a detailed review of the drug side effect profiles and a person-centered dialogue about goals and expectations.
View source ↗